Kezar Life Sciences, Inc. (KZR) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	—	—	—	7.0M	—
Cost of Revenue	176.0K	897.0K	—	—	—
Gross Profit	(176.0K)	(897.0K)	—	7.0M	—
Operating Expenses
R&D Expense	23.1M	33.8M	65.7M	85.7M	51.0M
SG&A Expense	18.3M	18.5M	23.4M	26.5M	20.2M
General & Admin Expense	18.3M	18.5M	23.4M	26.5M	20.2M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	436.0K	(897.0K)	1.5M	6.2M	—
Total Operating Expenses	41.8M	51.4M	90.6M	118.4M	71.2M
Cost and Expenses	34.6M	52.3M	90.6M	118.4M	71.2M
Operating Income (EBIT)	(42.0M)	(52.3M)	(90.6M)	(111.4M)	(71.2M)
Non-Operating
Interest Income	3.6M	4.4M	8.5M	11.1M	4.1M
Interest Expense	840.0K	—	1.6M	1.6M	1.2M
Net Interest Income	2.2M	4.4M	6.9M	9.6M	2.9M
Other Non-Op Income/Expense	(3.2M)	(3.8M)	6.9M	9.6M	2.9M
Non-Operating Income (excl Interest)	(2.2M)	—	(8.5M)	(11.1M)	(4.1M)
EBT (Pre-Tax Income)	(45.2M)	(56.0M)	(83.7M)	(101.9M)	(68.2M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(45.2M)	(56.0M)	(83.7M)	(101.9M)	(68.2M)
Earnings from Cont. Ops	(45.2M)	(56.0M)	(83.7M)	(101.9M)	(68.2M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(45.2M)	(56.0M)	(83.7M)	(101.9M)	(68.2M)
Per Share
Basic EPS	($6.17)	($7.66)	($1.15)	($1.40)	($1.01)
Diluted EPS	($6.17)	($7.66)	($1.15)	($1.40)	($1.01)
Revenue Per Share	$0.00	$0.00	$0.00	$0.10	$0.00
Shares
Basic Shares Outstanding	7.3M	7.3M	72.9M	72.6M	67.4M
Diluted Shares Outstanding	7.3M	7.3M	72.9M	72.6M	67.4M
Profitability Metrics
EBITDA	(39.1M)	(51.4M)	(81.1M)	(99.3M)	(66.0M)
D&A	646.0K	897.0K	1.0M	1.1M	1.0M
EBIT	(32.4M)	(52.3M)	(82.1M)	(100.3M)	(67.1M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026